title: Factors associated with frequent remission of microalbuminuria in patients with type 2 diabetes.
abstract: To estimate the frequency of remission/regression of microalbuminuria and to identify factors affecting such outcomes in Japanese patients with type 2 diabetes, we observed 216 patients with type 2 diabetes and microalbuminuria enrolled during an initial 2-year evaluation period for the next 6 years. Remission was defined as shift to normoalbuminuria and regression as a 50% reduction in urinary albumin excretion rate (AER) from one 2-year period to the next. Reduction of urinary AER was frequent, with a 6-year cumulative incidence of 51% (95% CI 42-60) for remission and 54% (45-63) for regression, whereas the frequency of progression to overt proteinuria was 28% (19-37). Microalbuminuria of short duration, the use of renin-angiotensin system-blocking drugs, and lower tertiles for HbA(1c) (<6.95%) and systolic blood pressure (<129 mmHg) were independently associated with remission or regression in the pooled logistic regression analysis. The results indicate that reduction in urinary AER occurs frequently in Japanese patients with type 2 diabetes. Early detection of microalbuminuria and a multifactorial control may result in improved outcomes for diabetic nephropathy and cardiovascular events.
authors.affiliation: Department of Medicine, Shiga University of Medical Science, Otsu, Shiga 520-2192, Japan. araki@belle.shiga-med.ac.jp
authors.forename: Shin-ichi
authors.initials: S
authors.lastname: Araki
authors.forename: Masakazu
authors.initials: M
authors.lastname: Haneda
authors.forename: Toshiro
authors.initials: T
authors.lastname: Sugimoto
authors.forename: Motohide
authors.initials: M
authors.lastname: Isono
authors.forename: Keiji
authors.initials: K
authors.lastname: Isshiki
authors.forename: Atsunori
authors.initials: A
authors.lastname: Kashiwagi
authors.forename: Daisuke
authors.initials: D
authors.lastname: Koya
mesh_terms: D000368:Aged; D000419:Albuminuria / Q000188:drug therapy*; D000704:Analysis of Variance; D047228:Angiotensin II Type 1 Receptor Blockers / Q000627:therapeutic use; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use; D001794:Blood Pressure; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy*; D005260:Female; D006442:Glycated Hemoglobin / Q000032:analysis; D006801:Humans; D007700:Kinetics; D008055:Lipids / Q000097:blood; D016015:Logistic Models; D008297:Male; D008875:Middle Aged; D011507:Proteinuria / Q000453:epidemiology; D012074:Remission Induction
chemical_list: D047228:Angiotensin II Type 1 Receptor Blockers; D000806:Angiotensin-Converting Enzyme Inhibitors; D006442:Glycated Hemoglobin; D008055:Lipids